Clinical Trials Browser

Phase 1 × Fulvestrant × 90 days × Clear all

NCT06257264 2026-06-05

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Phase 1 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07604571 2026-06-05

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

Phase 1 Recruiting

Advanced HR+/HER2- Breast Cancer

NCT05870579 2026-06-04

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT06756932 2026-06-04

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT07038369 2026-06-03

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Phase 1 Active not recruiting

BreastGenitourinaryGynecologic

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07226349 2026-06-03

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT03939897 2026-06-01

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Phase 1 Active not recruiting

24 enrolled 15 charts

Breast Neoplasms

NCT06120283 2026-05-27

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Phase 1 Recruiting

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07029399 2026-05-19

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Phase 1 Recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07318805 2026-05-08

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05683418 2026-04-22

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Phase 1 Recruiting

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT06997029 2026-04-21

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

Phase 1 Recruiting

Neoplasms

NCT05307705 2026-04-20

PIKASSO-01

Phase 1 Active not recruiting

Breast Neoplasms

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT07408089 2026-04-13

KOMODO-1

Phase 1 Recruiting

Breast Neoplasms

NCT07480681 2026-03-18

Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor

Phase 1 Not yet recruiting

Other solid neoplasm

Advanced/Metastatic Solid Tumors